. Author manuscript; available in PMC: 2016 May 1.

Published in final edited form as: Br J Dermatol. 2015 Apr 8;172(5):1329–1337. doi: 10.1111/bjd.13572

Table 3.

SF-36 scores of morphea patients compared with general U.S. populations, including healthy adults and those with selected diseases.

	N	PCS Mean (SD)	P value	MCS Mean (SD)	P value
Morphea	73	47.70 (12.48)	—	45.37 (11.41)	—
General U.S. Population	1982	50.00 (10.00)	.0565	50.00 (10.00)^*	<.0001
Healthy population	571	55.83 (5.34)^*	<.0001	52.48 (7.25)^*	<.0001
Back pain, sciatica	766	45.60 (10.84)	.1062	47.95 (10.97)	.0490
Depression	256	45.13 (12.54)	.0863	36.78 (11.60)^*	<.0001
Hypertension	503	44.08(11.56)^*	.0090	50.63 (10.00)^*	<.0001
Rheumatoid arthritis	133	41.66 (11.37)^*	<.0001	48.11 (11.22)	.0418
Diabetes	169	42.05 (11.49)^*	<.0001	48.24 (12.00)	.0454
Heart disease	184	39.36 (11.31)^*	<.0001	48.84 (11.44)	.0115
Systemic sclerosis	504	36.7 (11.2)^*	<.0001	49.0 (11.7)^*	.0094
Systemic lupus erythematosus	1316	36.3 (11.5)^*	<.0001	44.3 (11.8)	.4476
Fibromyalgia	2733	31.9 (9.6)^*	<.0001	41.9 (12.5)	.0197

To minimize associations made by chance alone, P values <0.01 were considered statistically significant.

Mean (SD) SF-36 scores for patients with morphea and other populations ^31-33 P values are shown as a comparison between mean norm-based SF-36 scores of morphea patients and those of other populations. Higher SF-36 scores indicate better HRQOL. *Significant finding (P <.01)